Bruker Just Bought Its Missing Piece. Revvity Launched AI That Sees What Humans Cannot. The Preclinical Imaging Market Is at a Turning Point
February 2025: Consolidation of Multimodal Pharmacokinetic Platforms
Bruker Corporation finalized the global rollout of its integrated optical/PET/MRI platform, a synchronized system designed to eliminate repeated animal anesthesia during complex disease studies. This followed the strategic acquisition of Spectral Instruments Imaging (SII), which filled the final gap in Bruker’s in-vivo optical imaging portfolio.
Impact: These coordinated moves position Bruker to lead a market scaling toward USD 7.03 Billion by 2032. Growth is increasingly driven by multi-modal imaging platforms that provide simultaneous anatomical, functional, and molecular data, allowing researchers to answer critical questions without sacrificing entire animal cohorts.
September 2025: AI-Driven Structural Shifts in Data Interpretation
Revvity (formerly PerkinElmer) launched its Living Image Synergy AI software platform, unifying analysis across multiple imaging modalities into a single interface. This innovation addresses the structural bottleneck of manually reconciling disparate datasets from optical, PET, and MRI environments.
Impact: For Contract Research Organizations (CROs), this automation is commercially decisive. By collapsing analysis into a continuous pipeline, firms can scale throughput without proportional headcount increases, reducing lead candidate identification timelines by an average of 23%.
Ongoing 2026: The Shift Toward Longitudinal Ethical Standards The market is pivoting toward non-invasive longitudinal tracking as the regulatory and ethical gold standard. In late 2025, the Advanced Preclinical Imaging Center (APIC) set a new benchmark for compliance in cardiovascular research, reflecting the industry’s move toward the 3Rs framework (Replacement, Reduction, Refinement).
Impact: Preclinical imaging has transitioned from a laboratory tool to financial risk management infrastructure. By providing an “early signal” of drug failure modes, these platforms help the pharmaceutical industry avoid the USD 1.4 Billion cost associated with late-stage clinical trial catastrophes.